Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea

AIDS

Volumn 14, Issue 3, 2000, Pages 273-278

  Moore, Richard D ^a   Wong, Wai Ming E ^a   Keruly, Jeanne C ^a   McArthur, Justin C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral; Didanosine; Hydroxyurea; Neuropathy; Stauvudine

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; HYDROXYUREA; STAVUDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY;

ADULT; AGED; ANTI-HIV AGENTS; DIDANOSINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYUREA; INCIDENCE; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 0034054491     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200002180-00009     Document Type: Article

References (16)

1. 1. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:153-161.
2. 2. Blum AS, Dal Pan GJ, Feinberg J, et al. Low-dose zalcitabine-related toxic neuropathy. Neurology 1996, 46:999-1003.
3. 3. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence, and management. Drug Safety 1998, 19:481-494.
4. 4. Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:169-174.
5. 5. Childs EA, Lyles RH, Selnes Ol, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999, 52:607-613.
6. 6. Bacellar H, Munoz A, Miller EN, et al Temporal trends in the incidence of HIV-1-related neurologie diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994, 44:1892-1900.
7. 7. Fisher M. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine. AIDS 1998, 12 (suppl 3):S9-S16.
8. 8. Gulick R. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents. AIDS 1998, 12 (suppl 3):S17-S22.
9. 9. Raffi F, Reliquet V, Auger S, et al. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients. AIDS 1998, 12:1999-2005.
10. 10. Lori F, Gallo RC. Hydroxyurea and AIDS: an old drug finds a new application? AIDS Res Hum Retroviruses 1995, 11:1149-1151.
11. 11. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV Clinical Practice Cohort. J Acquir Immune Defic Syndr 1998, 17(suppl 1 ):S38-S41.
12. 12. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Statistical Assoc 1989, 84:1074-1078.
13. 13. Feldman D, Brosnan C, Anderson TD. Ultrastructure of the peripheral neuropathy induced in rabbits in 2′,3′-dideoxycytidine. Lab Invest 1992, 66:75-85.
14. 14. Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine devidiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997, 11:185-190.
15. 15. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994, 266:801-885.
16. 16. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997, 11:1665-1670.